Response to superantigen stimulation in peripheral blood mononuclear cells from children perinatally infected with human immunodeficiency virus and receiving highly active antiretroviral therapy.
Our understanding of the pathogenesis of perinatal human immunodeficiency virus (HIV) infection is still evolving. We sought to characterize the response to the bacterial superantigen Staphylococcus enterotoxin B (SEB) of lymphocytes from HIV-infected children receiving treatment with highly active antiretroviral therapy (HAART). Using the flow cytometric methodology, we quantified apoptosis, proliferation, cytokine production, and activation antigen upregulation in CD4 and CD8 T lymphocytes following in vitro stimulation of peripheral blood mononuclear cells (PBMCs) with SEB. The levels of proliferation, CD4 interleukin-2 (IL-2) production, CD8 gamma interferon (IFN-gamma) production, and upregulation of CD69 expression by cells from HIV-infected children were indistinguishable from those by cells from controls. However, stimulation with SEB dramatically decreased the ratio of resting apoptotic cells to cycling apoptotic cells in the controls but not in the patients. In addition, unstimulated spontaneous apoptosis of CD4 T cells remained greater in the patients than in the controls. The percentages of IL-2-positive CD8 T cells and IFN-gamma-positive CD4 T cells following SEB stimulation were significantly lower in the patients than in the controls. Our multiparameter approach was able to demonstrate differences in lymphocyte superantigen responsiveness in HIV-infected children receiving HAART in comparison to that in uninfected controls, notably, an apoptotic versus a proliferative response to stimulation.
McCloskey
Thomas W
TW
North Shore-LIJ Research Institute, Immunology & Inflammation Center of Excellence, Department of Pediatrics, New York University School of Medicine, Manhasset, New York, USA.
Haridas
Viraga
V
Pontrelli
Lucy
L
Pahwa
Savita
S
D000293:Adolescent; D000328:Adult; D000942:Antigens, Bacterial / Q000494:pharmacology; D023241:Antiretroviral Therapy, Highly Active; D017209:Apoptosis / Q000187:drug effects; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D016022:Case-Control Studies; D049109:Cell Proliferation / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D016207:Cytokines / Q000096:biosynthesis; D004768:Enterotoxins / Q000494:pharmacology; D015658:HIV Infections / Q000188:drug therapy / Q000209:etiology / Q000276:immunology*; D006801:Humans; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000188:drug therapy / Q000209:etiology / Q000276:immunology*; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000276:immunology*; D008213:Lymphocyte Activation / Q000187:drug effects / Q000276:immunology; D018089:Superantigens / Q000494:pharmacology*
D000942:Antigens, Bacterial; D016207:Cytokines; D004768:Enterotoxins; D018089:Superantigens; C031818:enterotoxin B, staphylococcal